Biomarker ID | 49 |
PMID | 15289328 |
Year | 2004 |
Biomarker | phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-CD40/CD40L signaling, PI3K/PLC/TRK pathway,PI3K/PLC/TRK pathwayPI3K/AKT act,Inactivation of GSK3 by Akt causes accumulation of beta-catenin in alveolar macrophagesivation |
Experiment | PSA failure versus PSA non failure |
Type of Biomarker | Prognostic |
Cohort | 53 patients with PCa were selected for the study out of which 37 had PSA failure and 16 did not have PSA failure |
Senstivity | NA |
Specificity | NA |
AUC | 0.84 |
Accuracy | NA |
Level Of Significance | NA |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | total staining was scored as the product of the staining intensity (on a scale of 0–3) x the percentage of cells stained, resulting in a scale of 0–300 |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | AKT1, ERK |